Table 3.
Vaccine characteristics influencing vaccination acceptance by demographics (N = 19,702)
| Required doses of COVID-19 vaccinea | Effectiveness threshold of COVID-19 vaccineb | Adverse reactions of COVID-19 vaccinec | Duration of COVID-19 vaccine protectiond | Technology used in COVID-19 vaccinee | Producing country of COVID-19 vaccinef | |
|---|---|---|---|---|---|---|
| Weighted OR (95% CI) |
Weighted OR (95% CI) |
Weighted OR (95% CI) |
Weighted OR (95% CI) |
Weighted OR (95% CI) |
Weighted OR (95% CI) |
|
| Socio demography | ||||||
| Age group, years | ||||||
| 18–29 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 30–39 | 1.63 (1.41–1.87)*** | 0.72 (0.63–0.83)*** | 0.58 (0.49–0.68)*** | 1.01 (0.88–1.16) | 1.60 (1.03–2.47) | 0.99 (0.85–1.14) |
| 40–49 | 1.89 (1.61–2.22)*** | 0.53 (0.45–0.62)*** | 0.45 (0.38–0.54)*** | 0.99 (0.85–1.16) | 2.29 (1.4–3.75)*** | 0.91 (0.78–1.06) |
| 50–59 | 1.91 (1.59–2.28)*** | 0.61 (0.51–0.73)*** | 0.41 (0.34–0.51)*** | 0.98 (0.82–1.17) | 2.55 (1.52–4.29)*** | 0.81 (0.75–1.06) |
| 60 and above | 1.14 (0.93–1.387) | 0.69 (0.56–0.84)*** | 0.41 (0.33–0.51)*** | 1.01 (0.84–1.22) | 1.26 (0.71–2.26)* | 0.84 (0.69–1.02) |
| Gender | ||||||
| Male | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Female | 0.86 (0.78–0.96)** | 1.12 (1.01–1.25)* | 1.09 (0.97–1.23) | 1.07 (0.96–1.19) | 1.31 (1.08–1.57)*** | 1.08 (0.97–1.21) |
| Highest education level | ||||||
| Secondary school and below | 1.54 (1.27–1.85)** | 1.37 (1.12–1.68)*** | 1.04 (0.83–1.31) | 1.33 (1.10–1.61)*** | 0.79 (0.45–1.38) | 1.08 (0.90–1.30) |
| Certificate/A-Level/Diploma | 1.42 (1.21–1.66)*** | 0.78 (0.66–0.91)*** | 0.58 (0.49–0.69)*** | 0.91 (0.77–1.06) | 1.00 (0.64–1.59) | 1.04 (0.89–1.21) |
| Bachelor degree | 1.20 (1.04–1.38)*** | 0.99 (0.86–1.15) | 0.86 (0.73–1.01) | 1.04 (0.91–1.20) | 0.78 (0.49–1.25) | 0.84 (0.73–0.97)* |
| Postgraduate degree | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Ever delayed acceptance or refuse vaccine despite availability of vaccine service | ||||||
| Yes | 1.71 (1.49–1.96)*** | 1.77 (1.52–2.07)*** | 1.82 (1.52–2.16)*** | 1.52 (1.32–1.75)*** | 1.284(0.783–2.107) | 0.63 (0.55–0.73)*** |
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
Other gender was excluded due to small sample size
a: Only accept single dose vs Do not mind, b: Only accept 90% threshold vs Do not mind, c: Only accept minor adverse reactions vs Do not mind moderate adverse reactions, d: Only accept lesser than 12 months vs Do not mind moderate adverse reactions, e: Do not accept mRNA technology vs Do not know much about mRNA technology/Do not mind, f: Only accept a vaccine that is produced by specific countries vs Producing countries of a COVID-19 vaccine is not of my concern in vaccine choice
aP-value: P < 0.001; Nagelkerke R2: 0.044
bP-value: P < 0.001; Nagelkerke R2: 0.044
cP-value: 0.001; Nagelkerke R2: 0.066
dP-value: 0.001; Nagelkerke R2: 0.013
eP-value: 0.001; Nagelkerke R2: 0.013
fP-value: 0.010; Nagelkerke R2: 0.014
*P < 0.05, **P < <0.01, ***P < <0.001